Barclays PLC Ascendis Pharma A/S Transaction History

Barclays PLC

$357 Billion
Q4 2024

A detailed history of Barclays PLC transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Barclays PLC holds 28,976 shares of ASND stock, worth $4.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

28,976

Previous 18,736 54.65%

Holding current value

$4.4 Million

Previous $2.8 Million 42.62%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	BUY	$122.0 - $146.6 $1.25 Million - $1.5 Million	10,240 Added 54.65%	28,976 $3.99 Million
Q3 2024 Nov 15, 2024	SELL	$113.0 - $153.43 $30,284 - $41,119	-268 Reduced 1.41%	18,736 $2.8 Million
Q2 2024 Aug 14, 2024	SELL	$121.07 - $153.67 $250,372 - $317,789	-2,068 Reduced 9.81%	19,004 $2.59 Million
Q1 2024 May 15, 2024	BUY	$123.45 - $159.4 $462,567 - $597,271	3,747 Added 21.63%	21,072 $3.19 Million
Q4 2023 Feb 15, 2024	SELL	$86.1 - $127.36 $13,517 - $19,995	-157 Reduced 0.9%	17,325 $2.18 Million
Q3 2023 Nov 07, 2023	BUY	$86.5 - $103.97 $1.46 Million - $1.75 Million	16,874 Added 2775.33%	17,482 $1.64 Million
Q2 2023 Aug 03, 2023	SELL	$69.96 - $97.84 $4.78 Million - $6.68 Million	-68,294 Reduced 99.12%	608 $54,000
Q1 2023 May 04, 2023	BUY	$104.9 - $126.78 $1.28 Million - $1.55 Million	12,195 Added 21.51%	68,902 $7.39 Million
Q4 2022 Feb 13, 2023	SELL	$99.42 - $131.97 $6.77 Million - $8.99 Million	-68,114 Reduced 54.57%	56,707 $6.93 Million
Q3 2022 Nov 03, 2022	SELL	$84.03 - $110.23 $1.7 Million - $2.23 Million	-20,223 Reduced 13.94%	124,821 $12.9 Million
Q2 2022 Aug 12, 2022	BUY	$78.08 - $117.61 $11.3 Million - $17 Million	144,179 Added 16668.09%	145,044 $13.5 Million
Q1 2022 May 16, 2022	BUY	$102.18 - $135.75 $24,318 - $32,308	238 Added 37.96%	865 $102,000
Q4 2021 Feb 14, 2022	SELL	$127.1 - $169.66 $4.33 Million - $5.78 Million	-34,082 Reduced 98.19%	627 $84,000
Q3 2021 Nov 09, 2021	BUY	$112.67 - $176.92 $3.83 Million - $6.02 Million	34,024 Added 4967.01%	34,709 $5.53 Million
Q2 2021 Aug 13, 2021	SELL	$121.62 - $145.29 $407,913 - $487,302	-3,354 Reduced 83.04%	685 $90,000
Q1 2021 May 13, 2021	SELL	$124.92 - $173.33 $37,226 - $51,652	-298 Reduced 6.87%	4,039 $520,000
Q4 2020 Feb 11, 2021	BUY	$151.2 - $182.76 $32,659 - $39,476	216 Added 5.24%	4,337 $723,000
Q3 2020 Nov 12, 2020	BUY	$134.29 - $154.32 $18,532 - $21,296	138 Added 3.46%	4,121 $636,000
Q2 2020 Aug 12, 2020	BUY	$110.87 - $156.01 $405,118 - $570,060	3,654 Added 1110.64%	3,983 $589,000
Q1 2020 May 13, 2020	SELL	$97.01 - $145.11 $4,753 - $7,110	-49 Reduced 12.96%	329 $37,000
Q4 2019 Feb 10, 2020	SELL	$91.45 - $139.12 $752,907 - $1.15 Million	-8,233 Reduced 95.61%	378 $52,000
Q3 2019 Nov 14, 2019	BUY	$95.8 - $118.9 $796,385 - $988,415	8,313 Added 2789.6%	8,611 $829,000
Q2 2019 Aug 14, 2019	SELL	$107.11 - $132.09 $997,515 - $1.23 Million	-9,313 Reduced 96.9%	298 $34,000
Q1 2019 May 15, 2019	SELL	$62.15 - $129.99 $685,017 - $1.43 Million	-11,022 Reduced 53.42%	9,611 $1.13 Million
Q4 2018 Feb 14, 2019	BUY	$55.16 - $69.67 $861,213 - $1.09 Million	15,613 Added 311.02%	20,633 $1.29 Million
Q3 2018 Nov 14, 2018	BUY	$63.77 - $76.28 $8,736 - $10,450	137 Added 2.81%	5,020 $356,000
Q2 2018 Aug 14, 2018	SELL	$58.55 - $73.92 $22,073 - $27,867	-377 Reduced 7.17%	4,883 $325,000
Q1 2018 May 15, 2018	BUY	$38.98 - $68.04 $21,828 - $38,102	560 Added 11.91%	5,260 $345,000
Q4 2017 Feb 14, 2018	SELL	$31.98 - $40.38 $9,594 - $12,114	-300 Reduced 6.0%	4,700 $188,000
Q3 2017 Nov 14, 2017	BUY	$26.89 - $37.1 $134,450 - $185,500	5,000	5,000 $181,000

Others Institutions Holding ASND

# of Institutions

236

Shares Held

60.2M

Call Options Held

80.3K

Put Options Held

216K

View Full List

About Ascendis Pharma A/S

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $8.48B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

More about ASND

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account